Physician profile
Julia Cherrone
NPI 1891494175
$1,774.03
in general payments reported to CMS, 2019-2025
16 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $641 · 2024: $401 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $346.71 | 2023-2025 | Spravato |
| Corium, LLC | $293.56 | 2023-2025 | Azstarys |
| Abbvie INC. | $226.92 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $224.17 | 2023-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $183.91 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.72 | 2023-2025 | Caplyta |
| Lundbeck LLC | $78.59 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $59.79 | 2023 | Quviviq |
| Alkermes, INC. | $58.24 | 2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $52.86 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $30.86 | 2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $24.08 | 2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $19.74 | 2024 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $15.91 | 2023 | Farxiga |
| Vertical Pharmaceuticals, LLC | $15.11 | 2025 | Relexxii |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.86 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Cherrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.